Related Experiment Video
Updated: May 4, 2026
04:44
Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice
Published on: February 16, 2024
2.2K
Perampanel.
Dennis J Cada1, Terri L Levien2, Danial E Baker3
1Executive Editor, The Formulary.
Hospital Pharmacy
|January 15, 2014
Summary
The Formulary Monograph Service provides monthly drug monographs and utilization evaluations for Pharmacy & Therapeutics Committees. This service aids in informed drug selection and management for healthcare facilities.
Area of Science:
- Pharmacology
- Drug Utilization
- Healthcare Management
Background:
- Pharmacy & Therapeutics Committees require up-to-date drug information for formulary decisions.
- New drug releases and late-stage trial data necessitate timely evaluations.
- Effective medication use evaluations (MUE) are crucial for patient safety and cost-effectiveness.
Purpose of the Study:
- To provide subscribers with comprehensive monographs on new and emerging drugs.
- To deliver concise summaries for pharmacy and nursing in-service training.
- To offer detailed drug utilization/medication use evaluations (DUE/MUE) for specific agents.
Main Methods:
- Publication of 5-6 detailed monographs per month on newly released or late-phase drugs.
- Distribution of 1-page summary monographs for quick reference.
- Inclusion of a comprehensive drug utilization evaluation/medication use evaluation (DUE/MUE) monthly.
- Monthly drug class reviews published in cooperation with Hospital Pharmacy.
Main Results:
- Subscribers receive print and online access to monographs.
- Monographs can be customized to facility-specific needs.
- April 2013 topics included alogliptin, crofelemer, lomitapide, ponatinib, and sumatriptan iontophoretic transdermal.
- The DUE/MUE for April 2013 focused on alogliptin.
Conclusions:
- The Formulary Monograph Service supports informed drug management and clinical decision-making.
- The service provides valuable resources for Pharmacy & Therapeutics Committees and healthcare professionals.
- Regular updates and evaluations facilitate optimal drug therapy and formulary optimization.
More Related Videos
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
01:20Antiepileptic Drugs: Potassium Channel Activators
1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
1.0K
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:08Antiepileptic Drugs: Sodium Channel Blockers
2.4K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.4K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.4K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K